Vasculitis & polymyalgia rheumatica

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide

Arthritis Care Res (Hoboken)Published Retrospective cohort study

Authors' conclusion

Rates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.

Study context

Population
Incident users of rituximab or cyclophosphamide for antibody-associated vasculitis (AAV), TriNetX database, 2011 to 2022
Participants
1,461 AAV cases
Exposure
Prophylaxis vs no prophylaxis (adverse events); Pneumocystis jiroveci pneumonia (PJP) incidence during rituximab and/or cyclophosphamide induction and rituximab maintenance
Outcome
Incidence rate of PJP during induction therapy with rituximab and/or cyclophosphamide
Follow-up
First 6 months of induction therapy
Methodological detailsTriNetX electronic health records database, Cox proportional hazard models, adjusted analyses
  • TriNetX electronic health records database
  • Cox proportional hazard models
  • Adjusted analyses

Main finding

As reported in the abstract

PJP during induction therapy · first 6 months of induction

Cases of PJP

10

IR (cases per 1,000 patient-years)

15.0

Deaths

0

Observational data: associations, not effects.

Further findings

PJP during rituximab maintenance therapy (n = 709)

Cases of PJP
5
IR (cases per 1,000 person-years)
2.1
Deaths during PJP-associated hospitalization
1

Safety

OutcomeHR (95% CI)
LeukopeniaAdjusted analyses3.1 (1.1–8.6)
RashAdjusted analyses1.9 (1.0–3.6)
NephropathyAdjusted analyses2.6 (1.3–5.1)

Original publication

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). Published 28 October 2023. doi:10.1002/acr.25222

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.